165 results
6-K
EX-99.1
SNY
Sanofi
25 Apr 24
Sales growth of 6.7% at CER and business EPS(1) of €1.78
10:49am
strategy and complements 30-years of heritage in rare diseases and proven industry leadership in immunology and inflammation. This acquisition is subject …
Oncology
Cambodia
Rwanda
Health System Strengthening
Working with City Cancer, the objectives are to create city-wide oncology stakeholder leadership groups
6-K
EX-99.1
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
objectives toward 2025, built around three key pillars: building representative leadership, creating a work environment where employees can bring
6-K
EX-99.2
SNY
Sanofi
2 Feb 24
Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
1:21pm
.
François-Xavier will join from Nestle, where he has been the CFO for more than 8 years, providing strong financial leadership and driving sustainable … to Win Strategy. Under his leadership, our finance organization has been modernized into a team that supports our mission and execution of our
6-K
EX-99.1
SNY
Sanofi
1 Feb 24
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
9:45am
leadership in immunology. Looking forward, we remain committed to investing in R&D to fully unlock the value of our pipeline, powered by AI at scale …
In and beyond the workplace
Global Gender balance
Ambition of 50% of women in senior leadership roles by 2025
Ambition of 40% of women in executive
6-K
EX-99.1
SNY
Sanofi
23 Jan 24
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
7:23am
to pipeline
Acquisition supports Sanofi’s portfolio growth strategy and complements 30-year heritage in rare diseases and proven industry leadership
6-K
EX-99.1
lnkgti889u1vem c1qu
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
6-K
EX-99.1
zerpn7
20 Dec 23
Current report (foreign)
10:39am
6-K
6lxpthwe6glp7iu54e0
20 Dec 23
Current report (foreign)
10:39am
6-K
EX-99.2
uvo9tdu
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
6-K
EX-99.1
d3bu934w ad
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
6-K
EX-99.1
jrecj4evz4
10 Aug 23
Recommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee vote
9:50am
6-K
EX-99.1
qqaczk4kn9tld3wq
28 Jul 23
Solid Q2 performance and strong pipeline momentum
3:35pm
6-K
EX-99.2
tg9y929jj9it
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
obnhj2i1ctv
24 Jul 23
FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
12:43pm
6-K
EX-99.3
5a80d hybjk5x
5 Jul 23
Current report (foreign)
8:43am
6-K
EX-99.1
pqn6r3 s3
20 Jun 23
Current report (foreign)
10:18am
6-K
EX-99.1
jrqw6zgka5k jrd2
2 Jun 23
Approval of the financial statements for the fiscal year 2022
10:53am
6-K
EX-99.1
ew1xfi1dtxh9ewe6
27 Apr 23
Strong Q1 growth driven by Specialty Care, Vaccines and CHC
11:39am
6-K
EX-99.2
rc3do6kptspv zsa
24 Apr 23
Current report (foreign)
9:55am
6-K
EX-99.1
rplhop0vcxn2r
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am